Companion Diagnostics

Agenda Topics

• CDx in Emerging Markets (EU and Asia/Pacific)
• Circulating Biomarkers vs. Tissue-based Biomarkers for Companion Diagnostics Development
• Clinical Utility and Reimbursement for Companion Diagnostics: Payor Perspective
• Companion Diagnostics Regulatory Environment: Taking a Biomarker to CDx to Approval
• Converting LDTs to FDA Approved Tests
• Diagnostics and Pharmaceutical Companies Partnering for Companion Diagnostics Development
• Epigenetic Modifications (Hypermethylation of specific Genes) as Biomarkers for Diagnostics Development
• Next Generation Sequencing in Companion Diagnostics
• Platform Technologies for Building Companion Diagnostics
• Potential of microRNAs as Biomarkers for Diagnostics Development
• Protein Biomarkers versus Nucleic Acid Biomarkers for Companion Diagnostics Development
• The Future of Companion Diagnostics and New Areas of Development
• Cardiovascular and Metabolic Diseases
• Infectious Diseases
• Neuroscience
• US vs. EU Regulatory Landscape for Companion Diagnostics

Sponsorship and Exhibition Opportunities

Jeff Fan, Exhibition Manager
jeff@selectbioconferences.com
+1-510-857-4865

Confirmed Speakers to date

Anthony Altar, Chief Science Officer and Sr. Vice President, Assurex Health, Inc.
Nicholas Dracopoli, Vice President/Head, Johnson & Johnson
Brian Ellerman, Head, Technology Scouting and Information Science Innovation, Sanofi
Andrew Fish, Executive Director, AdvaMedDx
Walt Gall, VP of Healthcare and Strategic Partnerships, Saffron Technology
Christopher Jowett, Global Head, Abbott Molecular
Sylvie Le Gledic, Director IVD/CDx, Voisin Consulting Life Sciences
Thomas Li, Chief Technology Officer, A*STAR Singapore
Erick Lin, Manager, Illumina Inc
Matthew Marton, Director, Merck Research Laboratories
Charles Mathews, Vice President, Boston Healthcare
Jonathan Pan, Director, GlaxoSmithKline Oncology
Sunil Pandit, Senior Manager, Siemens Healthcare Diagnostics
Scott Patterson, Executive Director, Amgen Inc
Dan Rhodes, Head of Oncology Strategy, Thermo Fisher Scientific
Wolfgang Sadee, Professor, Ohio State University
John Schilling, Director & Advisor of Diagnostics, Eli Lilly & Co.
Nicole St Jean, Corporate Business Development, AstraZeneca
Frederic Sweeney, Senior Director, T2 Biosystems
Richard Watts, Vice President, QIAGEN

The Two Parallel Conference Tracks Maximize Networking between Pharmaceutical Delegates, Diagnostics Company Delegates, Tools/Technology Vendors, and Academics.

Panel Discussions and Round-Table Breakout Discussions are Included in the Conference Program with Extensive Opportunities for One-on-One Meetings and Networking.

All Conference Delegates, Speakers, and Exhibitors Receive Electronic Copies of Publications and Up-to-Date Reviews on CD.  These Reference Materials are a Valuable Resource to Complement the Conference Presentations.